hum0074 Release Note
|Research ID||Release Date||Type of Data|
|hum0074.v2||2018/09/25||GWAS for hepatocellular carcinoma (HCC) development after eradication of HCV by IFN-based treatment|
|hum0074.v1||2018/02/27||GWAS for patients with HCV infection (virologic response, platelet [PLT] reduction, and hemoglobin [Hb] reduction)|
A genome-wide association study for HCC development after eradication of HCV by IFN-based treatment (123 patients who developed HCC vs. 333 patients who did not develop HCC) was performed by using of Affymetrix Axiom Genome-Wide ASI 1 Array Plate (70 SNPs).
A genome-wide association studies for following symptoms were performed by using of Affymetrix Genome-Wide Human SNP Array 6.0.
(1) 78 null virologic response, 64 virologic response, and 51 sustained virologic response (43 SNPs)
(2) 107 HCV patients with decrease of PLT in response to PEG-IFN/RBV treatment and 196 HCV patients without decrease of PLT in response to PEG-IFN/RBV treatment (66 SNPs)
(3) 94 HCV patients with Hb reduction and 209 HCV patients without Hb reduction (32 SNPs)